WP
NKTR icon

Woodline Partners’s Nektar Therapeutics NKTR Stock Holding History

Woodline Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.9M Buy
415,335
+311,335
+299% +$17.7M 0.11% 248
2025
Q4 		$4.4M Sell
104,000
-129,059
-55% -$7.22M 0.02% 653
2025
Q3 		$13.3M Sell
233,059
-13,086
-5% -$433K 0.06% 373
2025
Q2 		$6.36M Buy
246,145
+20
+0% +$225 0.03% 518
2025
Q1 		$2.51M Sell
246,125
-85,509
-26% -$1.12M 0.02% 631
2024
Q4 		$4.63M Buy
331,634
+216,189
+187% +$3.81M 0.03% 501
2024
Q3 		$2.25M Buy
115,445
+73,918
+178% +$1.41M 0.02% 465
2024
Q2 		$772K Buy
+41,527
New +$875K 0.01% 478
2022
Q1 		– Sell
-65,774
Closed -$13.3M – 789
2021
Q4 		$13.3M Buy
+65,774
New +$14.3M 0.19% 148

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Woodline Partners's NKTR Position: Q1 2026 in Review

Woodline Partners increased its Nektar Therapeutics (NKTR) stake by 299% in Q1 2026, buying an estimated $17.7M and bringing the position to 415,335 shares worth $29.9M. The position accounts for 0.11% of the portfolio, ranked #248.

Woodline Partners first reported a position in NKTR in Q4 2021 and has held it in 9 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Woodline Partners held 415,335 shares of Nektar Therapeutics worth $29.9M as of Q1 2026.
  • Woodline Partners bought 311,335 Nektar Therapeutics shares in Q1 2026, an estimated $17.7M.
  • Nektar Therapeutics made up 0.11% of Woodline Partners's portfolio in Q1 2026, its #248 holding.
  • Woodline Partners first reported a position in Nektar Therapeutics in Q4 2021 and has held it in 9 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.